There are several established healthcare companies and startups in the Femtech space, which use disruptive technology including artificial intelligence, machine learning, big data, and the Internet of Things to develop interactive digital health applications for women's health. The majority of spending on other diseases has a male-specific research focus and this is separate from the research spending on male-specific conditions such as prostate cancer, which accounts for 2% of overall funding. Yet women today make up 49.6% of the total population and the economic burden for women's diseases is currently more than $500 billion. Additionally, with healthcare increasingly becoming personalized and patient-centric, now is the time to address the fundamental question of whether care delivery and management should be gender neutral. For several decades, healthcare products and solutions were designed, developed, and delivered without much attention to the fact that healthcare needs are different for men and women, considering their physiological differences.

For the first time, the US Food and Drug Administration has approved an artificial intelligence diagnostic device that doesn't need a specialized doctor to interpret the results. The software program, called IDx-DR, can detect a form of eye disease by looking at photos of the retina. It works like this: A nurse or doctor uploads photos of the patient's retina taken with a special retinal camera. The IDx-DR software algorithm first indicates whether the image uploaded is high-quality enough to get a result. Then, it analyzes the images to determine whether the patient does or does not have diabetic retinopathy, a form of eye disease where too much blood sugar damages the blood vessels in the back of the eye.

The Food and Drug Administration has approved the first artificial intelligence software that can decide, without a clinician's involvement, whether a patient might have a certain disease, the agency announced Wednesday. The software, called IDx-DR, looks for diabetic retinopathy, an eye disease that afflicts individuals with diabetes. With minimal training, health care providers can use a special camera to take a picture of the back of the patient's retina, which an algorithm then analyzes to look for the disease. If the software finds evidence of the disease, it recommends that a patient see an eye specialist. A computer program that can analyze medical images could save time and money, cutting down on unnecessary, expensive trips to specialists.

Marking a new era of "diagnosis by software," the US Food and Drug Administration on Wednesday gave permission to a company called IDx to market an AI-powered diagnostic device for ophthalmology. What it does: The software is designed to detect greater than a mild level of diabetic retinopathy, which causes vision loss and affects 30 million people in the US. It occurs when high blood sugar damages blood vessels in the retina. How it works: The program uses an AI algorithm to analyze images of the adult eye taken with a special retinal camera. A doctor uploads the images to a cloud server, and the software then delivers a positive or negative result.

An additional 84.1 million have prediabetes, which often leads to the full disease within five years. It's important to detect diabetes early to avoid health complications like heart disease, stroke, amputation of extremities and vision loss. Technology increasingly plays an important role in early detection, too. In that vein, the US Food and Drug Administration (FDA) has just approved an AI-powered device that can be used by non-specialists to detect diabetic retinopathy in adults with diabetes. Diabetic retinopathy occurs when the high levels of blood sugar in the bloodstream cause damage to your retina's blood vessels.

News and hype surround the field of radiology with headlines around the world purporting that it will be disrupted overnight. Few companies though really have the evidence to back up these claims. A combination of factors have led to this field being a target for innovators including the expansion of image archiving, the increase of diagnostic image-sharing and the computer-readable DICOM format. These innovative companies are seeking to apply AI, Machine and Deep Learning to this field in the hope of achieving time and cost savings, and to help doctors detect changes such as tumors, hardening of the arteries and provide highly accurate measurements of organs and blood flow. Even though in principal the challenges in this field are ripe for the application of modern technology, there are considerable market barriers new companies must face.

US health regulators have approved the first ever artificially intelligent medical device that can identify disease without need for a doctor. The device, called IDx-DR, is designed to detect the most common cause of vision loss among more than 30 million Americans living with diabetes. Its in-built camera takes a picture of the patient's eye, which is assessed by an algorithm to determine whether there are signs of diabetic retinopathy. The move, announced on Wednesday, makes this the first AI device to receive FDA approval to screen without need for a doctor to interpret the results. It means any doctor could use it, including primary care physicians who interact far more frequently with patients with diabetes, rather than patients having to seek out eye doctors themselves.

The device, called IDx-DR and produced by Iowa-based IDx LLC, is the first to receive Food and Drug Administration authorization that provides a screening decision without need for a clinician to also interpret the image or results. That makes it usable by health care providers not normally involved in eye care, such as primary care physicians who interact far more frequently with patients with diabetes. It was reviewed under new FDA regulations designed to speed to market some devices seen as low- to moderate-risk and for which there is no prior legally marketed device, part of Commissioner Scott Gottlieb's efforts to streamline approvals on a variety of fronts, including generic drugs and cheaper versions of costly biotech medicines. "The FDA will continue to facilitate the availability of safe and effective digital health devices that may improve patient access to needed health care," Malvina Eydelman, who oversees the agency's division of ophthalmic, and ear, nose and throat devices, said in a statement. IDx-DR will be used to detect diabetic retinopathy, in which high levels of blood sugar lead to damage in the blood vessels of the retina and vision loss.

N-Star generated jet of material shot outward at nearly speed of light.

Designing a new drug is a lengthy and expensive process. As the space of potential molecules is very large (10^23-10^60), a common technique during drug discovery is to start from a molecule which already has some of the desired properties. An interdisciplinary team of scientists generates hypothesis about the required changes to the prototype. In this work, we develop an algorithmic unsupervised-approach that automatically generates potential drug molecules given a prototype drug. We show that the molecules generated by the system are valid molecules and significantly different from the prototype drug. Out of the compounds generated by the system, we identified 35 FDA-approved drugs. As an example, our system generated Isoniazid - one of the main drugs for Tuberculosis. The system is currently being deployed for use in collaboration with pharmaceutical companies to further analyze the additional generated molecules.